Business Context and Reporting Period
Company: Schering-Plough Corporation (Note: The input metadata references Merck & Co., Inc., but the filing text is explicitly for Schering-Plough Corporation).
Reporting Period: Fiscal year ended December 31, 2005.
Overview: Schering-Plough is a global science-based health care company organized into three reportable segments: Prescription Pharmaceuticals, Consumer Health Care, and Animal Health. The company is in the "Turnaround" phase of a strategic Action Agenda initiated in 2003 to stabilize and repair the business. Financial performance in 2005 was heavily driven by the cholesterol franchise (VYTORIN and ZETIA) developed in a joint venture with Merck & Co., Inc., which is accounted for using the equity method.
Key Financial Metrics
| Metric | 2005 | 2004 | 2003 |
|---|---|---|---|
| Net Sales | $9,508 million | $8,272 million | $8,334 million |
| Income Before Taxes | $497 million | $(168) million | $(46) million |
| Net Income | $269 million | $(947) million | $(92) million |
| Net Income Available to Common Shareholders | $183 million | $(981) million | $(92) million |
| Diluted EPS | $0.12 | $(0.67) | $(0.06) |
| Operating Cash Flow | $882 million | $(154) million | $601 million |
| Research & Development | $1,865 million | $1,607 million | $1,469 million |
| Long-Term Debt | $2,399 million | $2,392 million | $2,410 million |
| Total Assets | $15,469 million | $15,911 million | $15,271 million |
Segment Profit (2005): Prescription Pharmaceuticals ($733 million), Consumer Health Care ($235 million), Animal Health ($120 million). Corporate and other expenses were $(591) million.
Equity Income: Equity income from the cholesterol joint venture with Merck was $873 million in 2005, a significant driver of profitability.
Material Changes vs. Prior Period
- Revenue Growth: Consolidated net sales increased 15% to $9.5 billion, driven by growth in REMICADE, PEG-INTRON, NASONEX, TEMODAR, and the inclusion of a full year of sales for AVELOX and CIPRO (licensed from Bayer).
- Profitability Turnaround: The company returned to profitability with $183 million in net income available to common shareholders, compared to a loss of $981 million in 2004. This improvement was primarily due to the cholesterol joint venture and reduced special charges relative to prior years.
- Special Charges: Total special charges were $294 million in 2005, down from $599 million in 2003. The 2005 charges included a $250 million increase in litigation reserves (totaling $500 million) related to government investigations, $28 million in employee termination costs, and $16 million in asset impairments.
- Product Performance:
- REMICADE: Sales increased 26% to $942 million.
- PEG-INTRON: Sales increased 33% to $751 million, aided by a Japan launch.
- CLARINEX: Sales decreased 7% due to generic competition (Allegra) and market contraction.
- OTC CLARITIN: Sales declined due to restrictions on pseudoephedrine (PSE) products.
Guidance, Outlook, Risks, and Contingencies
Outlook: Management anticipates continued growth in sales and profits from the cholesterol franchise in 2006. Gross margin improvements are expected to moderate due to royalty payments. R&D expenses are expected to grow faster than net sales due to clinical trial activity.
Key Risks and Contingencies:
- Legal and Regulatory Investigations: The company faces ongoing investigations by the U.S. Attorney's Office (Massachusetts), the Department of Justice, and state attorneys general regarding sales practices, off-label marketing, and Average Wholesale Price (AWP) calculations. A $500 million reserve has been established, but the company notes that settlement amounts could materially exceed this accrual.
- Patent Expirations and Generic Competition: Key products face patent expirations or generic entry (e.g., Pravachol, Zocor, Flonase, Allegra), which could materially impact sales and margins.
- Manufacturing Compliance: The company is operating under an FDA Consent Decree regarding Good Manufacturing Practices (cGMP). While significant steps were completed in 2005, third-party certification is pending. Failure to comply could result in additional penalties.
- Joint Venture Dependence: A significant portion of profits and cash flow depends on the Merck/Schering-Plough cholesterol joint venture. Changes in control provisions could result in the acquisition of these assets by Merck.
- Regulatory Pricing Pressure: Increasing pressure from managed care, government agencies, and international cost-containment programs threatens pricing power and reimbursement rates.
Important Facts for Investor Verification
- Litigation Reserve Adequacy: Verify if the $500 million litigation reserve is sufficient to resolve the Massachusetts, AWP, and state investigations, as the filing states settlements could exceed this amount.
- Cholesterol Joint Venture Performance: Monitor the sales trajectory of VYTORIN and ZETIA, as they are the primary drivers of the company's turnaround and future cash flow.
- FDA Consent Decree Status: Confirm the final certification of the cGMP Work Plan and whether any additional penalties are assessed by the FDA.
- Generic Competition Impact: Assess the actual impact of generic entries (Allegra, Flonase, Pravachol, Zocor) on the sales of CLARINEX, NASONEX, and the cholesterol franchise.
- U.S. Cash Flow Needs: Verify the company's ability to fund U.S. operations, which generate negative cash flow, using repatriated funds and operating cash flow from international operations.